Publications Mikhail V Blagosklonny

Mikhail V Blagosklonny

64 Publications

• Rejuvenating immunity: "anti-aging drug today" eight years later.

  • Mikhail V Blagosklonny

  Oncotarget

  Published on 31 Mar 2015

• Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.

  • Olga V Leontieva 
   
  • Zoya N Demidenko 
   
  • Mikhail V Blagosklonny

  Proceedings of the National Academy of Sciences of the United States of America

  Published on 17 Jun 2014

• Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.

  • Olga V Leontieva 
   
  • Geraldine M Paszkiewicz 
   
  • Mikhail V Blagosklonny

  Aging cell

  Published on 22 Mar 2014

• Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

  • Irina G Popovich 
   
  • Vladimir N Anisimov 
   
  • Mark A Zabezhinski 
   
  • Anna V Semenchenko 
   
  • Margarita L Tyndyk 
   
  • Maria N Yurova 
   
  • Mikhail V Blagosklonny

  Cancer biology & therapy

  Published on 20 Feb 2014

• M(o)TOR of pseudo-hypoxic state in aging: Rapamycin to the rescue.

  • Olga V Leontieva 
   
  • Mikhail V Blagosklonny

  Cell cycle (Georgetown, Tex.)

  Published on 23 Jan 2014

• Aging is not programmed: Genetic pseudo-program is a shadow of developmental growth.

  • Mikhail V Blagosklonny

  Cell cycle (Georgetown, Tex.)

  Published on 15 Dec 2013

• Immunosuppressants in cancer prevention and therapy.

  • Mikhail V Blagosklonny

  Oncoimmunology

  Published on 01 Dec 2013

• Selective anti-cancer agents as anti-aging drugs.

  • Mikhail V Blagosklonny

  Cancer biology & therapy

  Published on 27 Nov 2013

View All Publicationshttps://loop.frontiersin.org/people/227541/overview

When public mention today’s medicine, precision plays one of the most crucial roles and human lives are literally dependent on it. Hereby, any researches pertaining to medicine are required to meet the highest standards. The challenge nowadays is that any outcomes of researches can be shared online and used as a reference without being thoroughly verified and validated. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this problem and tried to create an alternative solution. That’s how a weekly oncology-focused research journal named “Oncotarget” has been founded back in 2010. The major principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to validate publications with Altmetric Article Reports that create “real-time feedback containing data summary related to a particular publication.” Oncotarget website provides a complete publications list with respective scores higher than 100 as well as reports mentioned previously. Mikhail (Misha) Blagosklonny glad to share his new approach and hopes it provides the necessary help to anybody, who has interest in oncology.
https://www.pathology.columbia.edu/diagnostic-specialties/personalized-genomic-medicine/oncology-testing/darwin-oncotarget-tm-oncotreat
“A diagnostic autoantibody signature for primary cutaneous melanoma” has the Altmetric score of 594. This study was published back in 2018 by Oncotarget and completed by diversified experts from Hollywood Private Hospital, Edith Cowan University, Dermatology Specialist Group, St. John of God Hospital and The University of Western Australia. The introduction of the study mentions that “recent data shows that Australians are four times more likely to develop a cancer of the skin than any other type of cancer”, and provides an insight on melanoma that “is curable by surgical excision in the majority of cases, if detected at an early stage.”
The paper has got an Altmetric score of 594. Mikhail (Misha) Blagosklonny realizes that majority of readers are aiming to comprehend the very meaning of it. Based on the Altmetric website, the score indicates “how many people have been exposed to and engaged with a scholarly output.” Hereby, the article about melanoma, was used for citations in various news articles 69 times. Moreover, it was referred to in 2 online blogs, as well as 25 Tweets on Twitter and 1 Facebook post. FOX23 of Tulsa, Oklahoma has headlined their report on July 20, 2018 as “New blood test could detect skin cancer early”, using the main content of Australia study
Another Oncotarget’s research with a top score of 476, is “Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moon-shot,”. This research has appeared in 60 news stories, 1 online blog post and 6 Twitter posts. The majority of public may have seen a concise overview only, however those who visit Mikhail (Misha) Blagosklonny at Oncotarget, do receive helpful scientific facts. Oncotarget is happy to have the chance to share with online readers this highly appreciated and top-quality information, that is trustworthy and reliable.
Misha Blagosklonny